查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2134669

荷爾蒙敏感性前列腺癌治療市場：全球市場預測，2026-2032年

Hormone Sensitive Prostate Cancer Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，荷爾蒙敏感性前列腺癌療法的市場規模將成長至 47.1 億美元，複合年成長率為 10.77%。

主要市場統計數據
基準年 2025 23億美元
預計年份：2026年 25.1億美元
預測年份：2032年 47.1億美元
複合年成長率 (%) 10.77%

荷爾蒙敏感性前列腺癌治療：執行摘要

荷爾蒙敏感性前列腺癌療法是指用於抑制雄性激素訊號傳導或減少雄性激素生成的治療方法，適用於對荷爾蒙療法仍有反應的患者。整體治療方案包括雄性激素剝奪療法、雄性激素受體路徑抑制劑、促性腺激素分泌釋放激素促效劑和拮抗劑以及聯合治療。臨床決策越來越依賴腫瘤大小、是否存在轉移、風險分級、既往治療史、合併症、耐受性、患者意願以及獲得專科醫療服務的途徑。本概述不提供市場估算或預測，而是著重介紹影響該領域發展的關鍵臨床、技術、區域和政策因素。

聯合治療和早期強化治療正在改變我們治療疾病的方式。

治療策略正從單純的荷爾蒙抑制轉向基於風險的聯合治療，包括雄性激素受體路徑抑制劑、化療、放射線治療或其他標靶治療。早期強化治療對於轉移性荷爾蒙敏感性疾病尤其重要，而對於局部性和復發性疾病，則需要根據復發風險和預期獲益來制定差異化的治療策略。隨著治療時間的延長，人們越來越關注心血管、代謝、骨骼、認知、性功能和生活品質（QOL）等方面的結局。實際改善措施包括更有系統的監測、多學科會診、患者參與式決策，以及在藥物依從性和耐受性的比較評估中更多地使用真實世界證據（RWE）。

利用人工智慧 (AI) 支援精準醫療、監測和證據產生。

人工智慧在影像診斷、風險分層、治療反應評估、臨床試驗招募和不利事件監測等領域中發揮日益重要的作用。機器學習工具可以幫助識別前列腺特異性抗原 (PSA) 動態變化、放射影像、病理學、基因組學和縱向記錄中具有臨床意義的模式，但其價值取決於具有代表性的訓練數據、外部檢驗、透明的性能指標以及與臨床工作流程的整合。人工智慧還可以輔助患者識別和藥物警戒，但仍需管治以解決偏見、隱私、可解釋性、網路安全以及臨床決策的課責。

區域洞察：醫療保健、診斷和醫療保健系統回應能力方面的差異。

北美地區通常受益於廣泛的專科醫生網路、先進的影像技術、活躍的臨床試驗以及獲得新型聯合治療的機會，但經濟負擔和保險要求可能會影響治療的連續性。歐洲擁有成熟的腫瘤醫療基礎設施，但在報銷制度、醫療技術評估和指南實施方面也存在國家間的差異。亞太地區的醫療體係高度發達，但在某些地區，診斷、放射治療、病理學和先進藥物的取得仍然有限。拉丁美洲面臨專科醫生分佈不均、藥品採購受限以及地理差異等問題。中東部分都市區擁有健全的醫療體系，但整體醫療服務的可近性並不穩定。非洲在早期診斷、癌症醫療專業人員的配備、藥品採購和治療連續性方面仍然面臨著嚴峻的挑戰。

群體特定洞察：經濟結構與夥伴關係驅動採用

在東協市場，保險覆蓋範圍、專科基礎設施、監管流程和藥品採購方面存在顯著差異，因此區域合作和靈活的診療路徑至關重要。金磚國家成員國擁有大規模的病患群體，公共和私人資金籌措模式也多元。本地生產、監管協調和診斷能力都會影響藥品的可近性。歐盟成員國在通用的法規結構下運作，但報銷決策由各國自行決定，執行資源有差異。七國集團（G7）的醫療衛生體系通常擁有強大的研究能力和腫瘤基礎設施，但預算影響和價值評估仍然是重大挑戰。海灣合作理事會（GCC）成員國通常擁有集中的專科基礎設施和採購能力，但醫療服務的可近性可能因居住地和醫療服務提供者網路而異。北約成員國的醫療衛生體系各不相同，這為在研究和供應韌性方面合作創造了機會，但治療機會並不均衡。

各國概況：各國的治療途徑決定了治療的可近性。

澳洲和加拿大擁有先進的臨床基礎設施，治療機會受公共藥品目錄、地區因素和專科醫生分佈的影響。巴西和墨西哥面臨著地區性不平等以及公立和私立醫療保健之間的差異。中國和印度的腫瘤治療能力不斷增強，但各省、各城市、各收入水準和保險覆蓋範圍之間存在顯著差異。在日本、韓國和英國，已建立以指引為基礎的體系，但報銷流程和證據要求會影響治療機會。法國、德國、義大利和西班牙受益於強大的專科醫生網路，但評估、協商和地區實施情況各不相同。在美國，患者可以廣泛獲得專科護理和參與臨床試驗的機會，但保險覆蓋範圍的設計、自付費用和差異會影響治療的連續性。在俄羅斯，治療機會取決於國內採購、地區醫療保健能力和專科腫瘤服務的可用性。

行業優先事項：改善證據、提高可及性和加強患者支持

產業領導者應優先考慮具有臨床意義的多方面證據，包括整體生存期、生活品質、功能性結局和治療負擔，而不是僅依賴生物標記和短期終點。他們還需要製定清晰的治療順序策略，加強對心血管和骨骼健康的監測，並透過教育和協調的追蹤來支持患者的用藥依從性。准入計畫應涵蓋報銷的合理性、公平的診斷、可靠的供應以及適合社區的交付模式。雖然與醫療保健系統的合作可以改善早期診斷和多學科診療，但負責任地使用人工智慧 (AI) 需要檢驗、隱私保護、實施後監測和臨床醫生監督。

調查方法：對臨床和醫療保健系統資訊來源。

本執行摘要系統地整合並分析了既定的臨床原則、監管和指南考慮、同行評審的證據、醫療保健系統現狀以及公開記錄的關於診斷、治療、監測和獲取醫療服務的模式。研究結果按治療方案的改變、人工智慧的應用、區域因素、經濟群體和國家的具體情況進行分類。解讀區分了普遍適用的臨床進展和區域實施條件。本摘要不包含市場估算、市場佔有率、預測或公司特定聲明。隨著指南、監管決策、比較證據和報銷政策的演變，結論應及時更新。

結論：整合且公平的醫療保健對於永續發展至關重要。

目前，荷爾蒙敏感性前列腺癌的治療現狀受到多種因素的影響，包括治療手段的改進、基於生物標記的患者篩選、監測手段的最佳化以及對生存率和生活品質（QOL）日益成長的重視。創新帶來的益處不僅取決於臨床療效，還取決於診斷系統的改進、治療費用的可負擔性、藥物依從性支持、多學科協作以及可靠的追蹤。那些能夠將可靠的實證醫學證據與負責任的技術應用以及以社區為基礎的醫療服務獲取策略相結合的領導者，將更有能力在不同的醫療保健系統中改善治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：荷爾蒙敏感性前列腺癌治療市場：依藥物類別分類

  • 雄性激素受體抑制劑
    • 第一代
    • 第二代
  • 雄性激素合成抑制劑
  • GnRH促效劑
  • GnRH拮抗劑

第8章：荷爾蒙敏感性前列腺癌治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內注射
    • 皮下注射

第9章：荷爾蒙敏感性前列腺癌治療市場：依治療線分類

  • 第 1 行
  • 第二行
  • 第三行

第10章：荷爾蒙敏感性前列腺癌治療市場：依患者年齡層別分類

  • 65歲或以上
  • 65歲以下

第11章：荷爾蒙敏感性前列腺癌治療市場：按報銷類型分類

  • 不在保險範圍內，也不需要自費。
  • 保險範圍

第12章：荷爾蒙敏感性前列腺癌治療市場：依最終用戶分類

  • 醫院
  • 零售藥房
  • 專科診所

第13章：荷爾蒙敏感性前列腺癌治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 批發商和經銷商

第14章：荷爾蒙敏感性前列腺癌治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：荷爾蒙敏感性前列腺癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：荷爾蒙敏感性前列腺癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Dendreon Pharmaceuticals LLC
  • Dr. Reddy's Laboratories Limited
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • Ipsen SA
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Myovant Sciences Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

第19章 主要專家

Product Code: MRR-F774F6337027

The Hormone Sensitive Prostate Cancer Drugs Market is projected to grow by USD 4.71 billion at a CAGR of 10.77% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.30 billion
Estimated Year [2026] USD 2.51 billion
Forecast Year [2032] USD 4.71 billion
CAGR (%) 10.77%

Hormone-Sensitive Prostate Cancer Drugs: Executive Summary

Hormone-sensitive prostate cancer drugs encompass therapies used to suppress androgen signaling or reduce androgen production in patients whose disease remains responsive to hormonal manipulation. The treatment landscape includes androgen-deprivation therapy, androgen-receptor pathway inhibitors, gonadotropin-releasing hormone agonists and antagonists, and combination regimens. Clinical decision-making increasingly depends on disease volume, metastatic status, risk classification, prior treatment, comorbidities, tolerability, patient preferences, and access to specialist care. This summary outlines the principal clinical, technological, regional, and policy forces shaping the field without presenting market estimates or forecasts.

Combination Care and Earlier Intensification Are Reshaping Treatment

Treatment is shifting from hormone suppression alone toward risk-adapted combinations that may include androgen-receptor pathway inhibition, chemotherapy, radiotherapy, or other directed approaches. Earlier intensification is particularly relevant for metastatic hormone-sensitive disease, while localized and recurrent disease require differentiated strategies based on recurrence risk and expected benefit. Longer treatment exposure has increased attention to cardiovascular, metabolic, skeletal, cognitive, sexual, and quality-of-life outcomes. Practical changes include more structured monitoring, multidisciplinary review, shared decision-making, and greater use of real-world evidence to evaluate adherence and comparative tolerability.

Artificial Intelligence Supports Precision, Monitoring, and Evidence Generation

Artificial intelligence is increasingly relevant to imaging interpretation, risk stratification, treatment-response assessment, clinical-trial recruitment, and adverse-event monitoring. Machine-learning tools may help identify clinically meaningful patterns in prostate-specific antigen kinetics, radiology, pathology, genomics, and longitudinal records, but their value depends on representative training data, external validation, transparent performance measures, and integration into clinical workflows. Artificial intelligence can also support patient identification and pharmacovigilance, while governance remains necessary to address bias, privacy, explainability, cybersecurity, and accountability for clinical decisions.

Regional Insights: Access, Diagnostics, and Health-System Capacity Differ

North America generally benefits from extensive specialist networks, advanced imaging, broad clinical-trial activity, and access to newer combination therapies, although affordability and insurance requirements can affect treatment continuity. Europe combines mature oncology infrastructure with country-level variation in reimbursement, health-technology assessment, and guideline implementation. Asia-Pacific includes highly developed systems alongside settings where diagnosis, radiotherapy, pathology, and advanced medicines remain less accessible. Latin America faces uneven specialist coverage, procurement constraints, and geographic disparities. The Middle East shows strong capacity in selected urban centers but heterogeneous access across health systems, while Africa continues to face substantial challenges involving early diagnosis, oncology workforce availability, medicine procurement, and continuity of care.

Group Insights: Economic and Alliance Structures Shape Adoption

ASEAN markets reflect wide differences in insurance coverage, specialist capacity, regulatory processes, and medicine procurement, making regional cooperation and adaptable care pathways important. BRICS members combine large patient populations with diverse public and private financing models; local manufacturing, regulatory coordination, and diagnostic capacity influence availability. European Union countries operate within shared regulatory structures but retain national reimbursement decisions and unequal implementation resources. G7 systems generally have strong research and oncology capabilities, while budget impact and value assessment remain important. GCC countries often possess concentrated specialist infrastructure and purchasing capacity, but access can vary by residency and provider network. NATO members span diverse health systems, creating opportunities for collaboration in research and supply resilience but not uniform treatment access.

Country Insights: National Pathways Determine Treatment Availability

Australia and Canada have advanced clinical infrastructure, with access shaped by public formulary decisions, geography, and specialist distribution. Brazil and Mexico face regional inequalities and differences between public and private care. China and India combine expanding oncology capabilities with substantial variation by province, city, income, and insurance coverage. Japan, South Korea, and the United Kingdom have established guideline-driven systems, while reimbursement pathways and evidence requirements influence uptake. France, Germany, Italy, and Spain benefit from strong specialist networks but differ in assessment, negotiation, and regional implementation. The United States offers broad access to specialized care and trials, yet coverage design, out-of-pocket exposure, and disparities affect treatment continuity. Russia's access is influenced by domestic procurement, regional capacity, and availability of specialized oncology services.

Industry Priorities: Improve Evidence, Access, and Patient Support

Industry leaders should prioritize clinically meaningful combination evidence, including overall survival, quality of life, functional outcomes, and treatment burden rather than relying on biomarker or short-term endpoints alone. They should develop clear sequencing strategies, strengthen cardiovascular and bone-health monitoring, and support adherence through education and coordinated follow-up. Access planning should address reimbursement evidence, equitable diagnostics, dependable supply, and locally appropriate delivery models. Partnerships with healthcare systems can improve early diagnosis and multidisciplinary care, while responsible use of artificial intelligence requires validation, privacy safeguards, post-deployment monitoring, and clinician oversight.

Methodology: Evidence Triangulation Across Clinical and Health-System Sources

This executive summary uses a structured synthesis of established clinical principles, regulatory and guideline considerations, peer-reviewed evidence, health-system context, and publicly documented patterns in diagnosis, treatment, monitoring, and access. Findings are organized by therapeutic change, artificial-intelligence application, geography, economic grouping, and country context. Interpretation distinguishes broadly applicable clinical developments from local implementation conditions. No market estimates, market shares, forecasts, or company-specific claims are included; conclusions should be updated as guidelines, regulatory decisions, comparative evidence, and reimbursement policies evolve.

Conclusion: Durable Progress Depends on Integrated, Equitable Care

The hormone-sensitive prostate cancer drug landscape is being shaped by treatment intensification, biomarker-informed selection, improved monitoring, and growing emphasis on survivorship and quality of life. The benefits of innovation will depend not only on clinical efficacy, but also on diagnostic readiness, affordability, adherence support, multidisciplinary capacity, and reliable follow-up. Leaders who combine robust evidence generation with responsible technology deployment and regionally tailored access strategies will be better positioned to improve outcomes across heterogeneous health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hormone Sensitive Prostate Cancer Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Androgen Receptor Inhibitors
    • 7.2.1. First Generation
    • 7.2.2. Second Generation
  • 7.3. Androgen Synthesis Inhibitors
  • 7.4. GnRH Agonists
  • 7.5. GnRH Antagonists

8. Hormone Sensitive Prostate Cancer Drugs Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
    • 8.3.1. Intramuscular Injection
    • 8.3.2. Subcutaneous Injection

9. Hormone Sensitive Prostate Cancer Drugs Market, by Therapy Line

  • 9.1. Introduction
  • 9.2. First Line
  • 9.3. Second Line
  • 9.4. Third Line

10. Hormone Sensitive Prostate Cancer Drugs Market, by Patient Age Group

  • 10.1. Introduction
  • 10.2. 65 Years And Above
  • 10.3. Under 65 Years

11. Hormone Sensitive Prostate Cancer Drugs Market, by Reimbursement Type

  • 11.1. Introduction
  • 11.2. Non Reimbursed Or Out Of Pocket
  • 11.3. Reimbursed

12. Hormone Sensitive Prostate Cancer Drugs Market, by End User

  • 12.1. Introduction
  • 12.2. Hospitals
  • 12.3. Retail Pharmacies
  • 12.4. Specialty Clinics

13. Hormone Sensitive Prostate Cancer Drugs Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacy
  • 13.3. Online Pharmacy
  • 13.4. Retail Pharmacy
  • 13.5. Wholesalers & Distributors

14. Hormone Sensitive Prostate Cancer Drugs Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Europe
  • 14.6. Middle East
  • 14.7. Africa

15. Hormone Sensitive Prostate Cancer Drugs Market, by Group

  • 15.1. Introduction
  • 15.2. ASEAN
  • 15.3. GCC
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. G7
  • 15.7. NATO

16. Hormone Sensitive Prostate Cancer Drugs Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. United Kingdom
  • 16.7. Germany
  • 16.8. France
  • 16.9. Russia
  • 16.10. Italy
  • 16.11. Spain
  • 16.12. China
  • 16.13. India
  • 16.14. Japan
  • 16.15. Australia
  • 16.16. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. Amgen Inc.
  • 18.3. Astellas Pharma Inc.
  • 18.4. AstraZeneca plc
  • 18.5. Bayer AG
  • 18.6. Boehringer Ingelheim International GmbH
  • 18.7. Bristol-Myers Squibb Company
  • 18.8. Dendreon Pharmaceuticals LLC
  • 18.9. Dr. Reddy's Laboratories Limited
  • 18.10. Ferring International Center S.A.
  • 18.11. GlaxoSmithKline plc
  • 18.12. Ipsen S.A.
  • 18.13. Johnson & Johnson
  • 18.14. Merck & Co., Inc.
  • 18.15. Myovant Sciences Inc.
  • 18.16. Novartis AG
  • 18.17. Orion Corporation
  • 18.18. Pfizer Inc.
  • 18.19. Roche Holding AG
  • 18.20. Sanofi S.A.
  • 18.21. Sun Pharmaceutical Industries Ltd.
  • 18.22. Takeda Pharmaceutical Company Limited
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. Viatris Inc.

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Hormone Sensitive Prostate Cancer Drugs Market, Years Considered for the Study
  • FIGURE 2. Global Hormone Sensitive Prostate Cancer Drugs Market, Research Design
  • FIGURE 3. Global Hormone Sensitive Prostate Cancer Drugs Market, Research Framework
  • FIGURE 4. Global Hormone Sensitive Prostate Cancer Drugs Market, Data Triangulation
  • FIGURE 5. Global Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
  • FIGURE 7. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2025 vs 2032 (%)
  • FIGURE 11. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2025 vs 2032 (%)
  • FIGURE 13. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2025 vs 2032 (%)
  • FIGURE 15. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 17. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 19. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Hormone Sensitive Prostate Cancer Drugs Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Hormone Sensitive Prostate Cancer Drugs Market Segmentation & Coverage
  • TABLE 2. Global Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 4. Global Androgen Receptor Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Androgen Receptor Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Androgen Receptor Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global First Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global First Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global First Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Second Generation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Second Generation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Second Generation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Androgen Synthesis Inhibitors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Androgen Synthesis Inhibitors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Androgen Synthesis Inhibitors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global GnRH Agonists Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global GnRH Agonists Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global GnRH Agonists Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global GnRH Antagonists Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global GnRH Antagonists Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global GnRH Antagonists Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 23. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Intramuscular Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Intramuscular Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Intramuscular Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 36. Global First Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global First Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global First Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Third Line Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Third Line Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Third Line Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 46. Global 65 Years And Above Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global 65 Years And Above Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global 65 Years And Above Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Under 65 Years Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Under 65 Years Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Under 65 Years Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 53. Global Non Reimbursed Or Out Of Pocket Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Non Reimbursed Or Out Of Pocket Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Non Reimbursed Or Out Of Pocket Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Reimbursed Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Reimbursed Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Reimbursed Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 60. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 70. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Wholesalers & Distributors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Wholesalers & Distributors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Wholesalers & Distributors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 85. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 86. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 93. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 95. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 96. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 97. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 98. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 99. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 100. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 101. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 102. North America Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 103. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 105. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 106. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 107. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 108. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 109. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 110. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 111. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 112. Latin America Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 113. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 115. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 116. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 117. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 118. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 119. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 120. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 121. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 122. Europe Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 123. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 125. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 126. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 127. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 128. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 129. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 130. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 131. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 132. Middle East Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 133. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 134. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 135. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 136. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 137. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 138. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 139. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 140. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 141. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 142. Africa Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 143. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 145. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 146. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 147. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 148. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 149. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 150. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 151. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 152. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 153. ASEAN Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 154. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 155. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 156. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 157. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 158. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 159. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 160. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 161. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 162. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 163. GCC Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 164. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 165. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 166. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 167. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 168. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 169. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 170. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 171. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 172. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 173. European Union Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 174. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 175. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 176. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 177. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 178. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 179. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 180. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 181. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 182. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 183. BRICS Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 184. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 185. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 186. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 187. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 188. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 189. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 190. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 191. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 192. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 193. G7 Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 194. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 195. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 196. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 197. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 198. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 199. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 200. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 201. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 202. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 203. NATO Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 204. Global Hormone Sensitive Prostate Cancer Drugs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 205. United States Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 206. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 207. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 208. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 209. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 210. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 211. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 212. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 213. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 214. United States Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 215. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 216. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 217. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 218. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 219. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 220. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 221. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 222. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 223. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 224. Canada Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 225. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 226. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 227. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 228. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 229. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 230. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 231. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 232. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 233. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 234. Mexico Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 235. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 236. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 237. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 238. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 239. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 240. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 241. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 242. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 243. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 244. Brazil Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 245. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 246. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 247. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 248. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 249. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 250. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 251. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 252. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 253. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 254. United Kingdom Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 255. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 256. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 257. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 258. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 259. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 260. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 261. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 262. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 263. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 264. Germany Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 265. France Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 266. France Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 267. France Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 268. France Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 269. France Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 270. France Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 271. France Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 272. France Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 273. France Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 274. France Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 275. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 276. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 277. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 278. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 279. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 280. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 281. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 282. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 283. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 284. Russia Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 285. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 286. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 287. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 288. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 289. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 290. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 291. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 292. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 293. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 294. Italy Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 295. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 296. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
  • TABLE 297. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by Androgen Receptor Inhibitors, 2017-2032 (USD Million)
  • TABLE 298. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by Mode Of Administration, 2017-2032 (USD Million)
  • TABLE 299. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by Parenteral, 2017-2032 (USD Million)
  • TABLE 300. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by Therapy Line, 2017-2032 (USD Million)
  • TABLE 301. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 302. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by Reimbursement Type, 2017-2032 (USD Million)
  • TABLE 303. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 304. Spain Hormone Sensitive Prostate Cancer Drugs Market Size, by Distribution Channel, 2017